Ecromeximab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | GD3 ganglioside |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number |
292819-64-8  |
| ChemSpider | none |
| UNII |
M76FX2JZRM  |
| Chemical and physical data | |
| Molar mass | 145,255 g/mol |
| (what is this?) (verify) | |
Ecromeximab is a chimeric monoclonal antibody being developed for the treatment of malignant melanoma.[1][2]
The drug was developed by Kyowa Hakko Kogyo Co., Ltd. As of December 2015 development had been discontinued.[3]
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Ecromeximab, American Medical Association.
- ↑ Clinical trial number NCT00679289 for "Phase II Study of KW2871 Combined With High Dose Interferon-alpha2b in Patients With Metastatic Cutaneous Melanoma" at ClinicalTrials.gov
- ↑ Adis insight: Ecromeximab
This article is issued from Wikipedia - version of the 8/13/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.